文献速递消化系统肿瘤

新辅助托里帕利单抗联合塞来昔布对比单药治疗dMMR/MSI-H局部晚期结直肠癌的2期随机试验

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2026-07-01

PICC-2研究纳入110例dMMR或MSI-H局部晚期结直肠癌患者,随机接受新辅助托里帕利单抗联合塞来昔布或托里帕利单抗单药治疗。联合组病理完全缓解率为89%,单药组为69%,组间差异19个百分点(95%CI 4-34;

要点

  • 联合塞来昔布组病理完全缓解率89%,单药组69%,差异有统计学意义。
  • 两组3级治疗相关不良事件发生率分别为5%和7%,无4级或5级事件。
  • 联合方案支持在更大规模3期试验中进一步研究。

核心结论

  • 在dMMR或MSI-H局部晚期结直肠癌中,新辅助托里帕利单抗联合塞来昔布较单药显著提高病理完全缓解比例,安全性相似。

研究设计与样本

  • PICC-2为多中心、开放标签、随机对照2期试验,在中国3家学术医院开展。
  • 共110例患者按1:1随机分配至托里帕利单抗联合塞来昔布组(n=55)或托里帕利单抗单药组(n=55)。

主要发现

  • 联合组53/55(96%)和单药组51/55(93%)患者接受了手术。
  • 两组分别有49/55(89%)患者完成全部12周期新辅助治疗。
  • 3级治疗相关不良事件:联合组3例(5%),单药组4例(7%);无4级或5级事件。

临床怎么用

  • 对于dMMR或MSI-H局部晚期结直肠癌,可考虑新辅助托里帕利单抗联合塞来昔布以提高病理完全缓解率。
  • 联合方案安全性可控,与单药治疗相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immune checkpoint blockade has shown remarkable activity in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), locally advanced colorectal cancer. Preclinical studies suggest that COX-2 inhibition might modulate the inflammatory tumour microenvironment and augment the effect of PD-1 blockade. We aimed to investigate whether the addition of the COX-2 inhibitor celecoxib to neoadjuvant toripalimab would increase the pathological complete response in this population. METHODS: PICC-2 was a multicentre, open-label, randomised, controlled, phase 2 trial conducted at three academic hospitals in China. Eligible patients were aged 18-75 years; had histologically confirmed dMMR or MSI-H colorectal cancer, of clinical stage T3-T4 or any clinical T stage with lymph node positivity (N+); had an Eastern Cooperative Oncology Group performance status score of 0 or 1; and had adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1) via an interactive web response system, stratified by tumour location and clinical T stage, to receive neoadjuvant toripalimab plus celecoxib or toripalimab monotherapy every 14 days for 12 cycles, followed by surgery. Toripalimab 3 mg/kg was administered intravenously on day 1 in both groups; patients in the toripalimab plus celecoxib group also received celecoxib 200 mg orally twice daily on days 1-14. The primary endpoint was the proportion of patients with pathological complete response, defined as no presence of residual viable tumour in the primary tumour and all sampled lymph nodes at surgery, assessed by central blinded independent pathological review in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03926338, and is ongoing. FINDINGS: Between May 5, 2022, and Jan 20, 2025, 110 patients were randomly assigned to toripalimab plus celecoxib (n=55) or toripalimab monotherapy (n=55). Overall, 65 (59%) patients were male, all patients were Chinese, 76 (69%) had cT4 tumours, and 105 (95%) had clinically node-positive disease. At the data cutoff date (Oct 10, 2025), median follow-up was 18·1 months (IQR 11·5-25·3). 49 (89%) of 55 patients in each group completed all 12 planned cycles of neoadjuvant therapy. Surgery was done in 53 (96%) of 55 patients in the toripalimab plus celecoxib group and 51 (93%) of 55 in the monotherapy group. Pathological complete response was observed in 49 of 55 patients (89% [95% CI 78-96]) in the toripalimab plus celecoxib group versus 38 of 55 (69% [55-81]) in the monotherapy group (between-group difference 19 percentage points [95% CI 4-34]; p=0·014). Grade 3 treatment-related adverse events occurred in three (5%) patients and four (7%) patients, respectively; grade 3 treatment-related adverse events were tumour perforation (two [4%]) and bowel obstruction (one [2%]) in the toripalimab plus celecoxib group, and rash (one [2%]), tumour perforation (one [2%]), increased aminotransferase (one [2%]), and hypothyroidism (one [2%]) in the monotherapy group. No grade 4 or 5 treatment-related adverse events occurred. INTERPRETATION: In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials. FUNDING: The National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research, the National Key Clinical Discipline of China, the Program of Guangdong Provincial Clinical Research Center for Digestive Diseases, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hu H, Shen X, Li Y, et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2026. PMID: 42385761. doi:10.1016/S1470-2045(26)00220-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。